Yes, patients might use it off-label as mono, or MDR2+ patients will throw the others pills away and use it as a monotherapy.

Yes, as per Nader's comments and the quarterly report, pivotal will start pending enough funding... I agree with ohm that they could do a slow ramp-up though...